MESOBLAST LIMITED - Announcements

0.66%

$2.31

Market Cap $2.950B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

MSB	Key Patent Allowed In Japan For Heart Diseases, Stroke	PRICE SENSITIVE	27/03/15	73.02KB	Share
MSB	Fast Track Access To Potential Japan Investment Incentives	PRICE SENSITIVE	19/03/15	84.21KB	Share
MSB	Results Show Improved Survival in Children with GVHD	PRICE SENSITIVE	16/02/15	345.52KB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	12/02/15	499.71KB	Share
MSB	Key US patent granted for treatment of degenerated discs	PRICE SENSITIVE	10/02/15	67.56KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	259.08KB	Share
MSB	P3 trial initiated, positive 24 mth P2 results in back pain	PRICE SENSITIVE	15/01/15	99.1KB	Share
MSB	Key Mesoblast Patent Claims Upheld in Europe	PRICE SENSITIVE	16/12/14	84.5KB	Share
MSB	Chronic Low Back Pain Results Presented at NASS	PRICE SENSITIVE	13/11/14	1.11MB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	253.61KB	Share
MSB	MSB PARTNER JCR FILES FOR PRODUCT APPROVAL	PRICE SENSITIVE	01/10/14	286.25KB	Share
MSB	MSB Unveils Path to Bring its Key Products to Market	PRICE SENSITIVE	26/08/14	423.24KB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	26/08/14	1.53MB	Share
MSB	MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure	PRICE SENSITIVE	07/08/14	90.85KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/14	255.04KB	Share
MSB	Circulation Publishes Improved Outcomes with Mesoblast Cells	PRICE SENSITIVE	25/06/14	339.78KB	Share
MSB	Mesoblast Receives $5.05m for Stem Cell Pipeline Development	PRICE SENSITIVE	16/06/14	61.45KB	Share
MSB	Response to ASX Price Query	PRICE SENSITIVE	06/06/14	115.33KB	Share
MSB	MSB Accelerates Plans for Commercial Manufacturing Operation	PRICE SENSITIVE	28/05/14	248.58KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/14	187.82KB	Share
MSB	MESOBLAST PROVIDES UPDATE ON CLINICAL PROGRAMS OF PROCHYMAL	PRICE SENSITIVE	29/04/14	153.9KB	Share
MSB	Response to ASX price query	PRICE SENSITIVE	08/04/14	227.71KB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/14	360KB	Share
MSB	Key European Patent Granted for Mesoblast's MPCs	PRICE SENSITIVE	20/02/14	102.94KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	245.07KB	Share
MSB	Positive Disc Repair Results Using Mesoblast Stem Cells	PRICE SENSITIVE	30/01/14	345.69KB	Share
MSB	Mesoblast Reports Positive Type 2 Diabetes Trial Results	PRICE SENSITIVE	04/12/13	335.25KB	Share
MSB	New Japanese Regenerative Medicine Legislation	PRICE SENSITIVE	25/11/13	282.6KB	Share
MSB	MPCs Strengthen Cardiac Function in End-Stage Heart Failure	PRICE SENSITIVE	19/11/13	253.28KB	Share
MSB	Improved Survival in Children with GvHD After Cell Therapy	PRICE SENSITIVE	14/11/13	110.33KB	Share
MSB	MPCs Induce Functional Recovery in Ischemic Stroke Model	PRICE SENSITIVE	11/11/13	99.23KB	Share
MSB	FDA Clears Phase 3 Heart Failure Trial	PRICE SENSITIVE	31/10/13	119.64KB	Share
MSB	MSBs Registration Plans for GVHD Cell Product in Japan	PRICE SENSITIVE	28/10/13	84.06KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/13	160.91KB	Share
MSB	Mesoblast, Intrexon and Ziopharm to Target Cancers	PRICE SENSITIVE	24/10/13	516.36KB	Share
MSB	Mesoblast Acquires Osiris' Cultured Stem Cell Business	PRICE SENSITIVE	11/10/13	124.44KB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	29/08/13	741.39KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	01/08/13	185.86KB	Share
MSB	MSB Receives $4.3M Pipeline Funds from Australian Government	PRICE SENSITIVE	18/07/13	61.17KB	Share
MSB	MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy	PRICE SENSITIVE	26/06/13	130.63KB	Share
MSB	Key Mesenchymal Precursor Cell Patent Granted in Japan	PRICE SENSITIVE	05/06/13	102.76KB	Share
MSB	Circulation Research Publishes AMI Preclinical Trial Results	PRICE SENSITIVE	15/05/13	225.19KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	169.64KB	Share
MSB	POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIR	PRICE SENSITIVE	22/04/13	386.62KB	Share
MSB	Mesoblast Enters into Agreements to Raise A$170million	PRICE SENSITIVE	06/03/13	366.18KB	Share
MSB	Trading Halt	PRICE SENSITIVE	04/03/13	197.58KB	Share
MSB	Half-Year Results & Strategic Update on Product Development	PRICE SENSITIVE	11/02/13	339.47KB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	11/02/13	369.39KB	Share
MSB	KEY MPC PATENTS GRANTED IN UNITED STATES AND CHINA	PRICE SENSITIVE	07/02/13	53.33KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	184.56KB	Share
MSB	FDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS	PRICE SENSITIVE	30/01/13	63.82KB	Share
MSB	Positive Results in Phase 2 Lumbar Spinal Fusion Trial	PRICE SENSITIVE	11/01/13	230.78KB	Share
MSB	Mesoblast Corporate Overview - CEO Message to AGM	PRICE SENSITIVE	29/11/12	233.18KB	Share
MSB	Key Manufacturing Agreement with FDA for Phase 3 Trials	PRICE SENSITIVE	20/11/12	130.26KB	Share
MSB	Price Query	PRICE SENSITIVE	15/11/12	166.61KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	185.41KB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	22/08/12	1.69MB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	174.29KB	Share
MSB	Rheumatoid Arthritis New Major Clinical Target for MSB	PRICE SENSITIVE	24/07/12	159.97KB	Share
MSB	Response to ASXPrice Query	PRICE SENSITIVE	18/06/12	190.73KB	Share
MSB	MSB Provides Corporate Strategy For Neurologic Product	PRICE SENSITIVE	08/06/12	1MB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	189.32KB	Share
MSB	Intervertebral Disc Repair Phase 2 Trial Update	PRICE SENSITIVE	17/04/12	129.89KB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/12	553.2KB	Share
MSB	FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes	PRICE SENSITIVE	31/01/12	151.27KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	12/01/12	130.08KB	Share
MSB	Positive Outcome From FDA Meeting For Diabetes Program	PRICE SENSITIVE	22/11/11	213.39KB	Share
MSB	Positive Heart Failure Trial Results Presented to AHA	PRICE SENSITIVE	15/11/11	226.43KB	Share
MSB	Positive Results Using Adult Stem Cells for Type 2 Diabetes	PRICE SENSITIVE	10/11/11	795.25KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/11	132.31KB	Share
MSB	Response to ASX Price Query Letter	PRICE SENSITIVE	28/10/11	179.75KB	Share
MSB	Clearance for First Phase 2 Clinical Trial for Eye Diseases	PRICE SENSITIVE	24/10/11	228.55KB	Share
MSB	Licensing Executives Society Deals of Distinction Award	PRICE SENSITIVE	20/10/11	198.97KB	Share
MSB	MSB and Lonza form strategic global manufacturing alliance	PRICE SENSITIVE	27/09/11	29.85KB	Share
MSB	First European Trial for Heart Attack Treatment Cleared	PRICE SENSITIVE	05/09/11	227.7KB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	24/08/11	599.08KB	Share
MSB	First Minimally Invasive Procedure for Lumbar Disc Repair	PRICE SENSITIVE	22/08/11	202.43KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	01/08/11	177.38KB	Share
MSB	FDA Clearance for Phase 3 Bone Marrow Transplant Trial	PRICE SENSITIVE	07/07/11	230.27KB	Share
MSB	FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease	PRICE SENSITIVE	29/06/11	144.65KB	Share
MSB	Key Product Franchises Featured at Nomura Asia Equity Forum	PRICE SENSITIVE	14/06/11	960.14KB	Share
MSB	Revascor Increases Blood Supply to Damaged Heart Muscle	PRICE SENSITIVE	09/06/11	252.13KB	Share
MSB	Key USA Patents Increase Commercial Rights and Indications	PRICE SENSITIVE	24/05/11	145.42KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	02/05/11	128.9KB	Share
MSB	Mesoblast Included in S and P/ASX 200 Index	PRICE SENSITIVE	18/04/11	153.75KB	Share
MSB	Mesoblast Update on Valeant Proposal to Cephalon	PRICE SENSITIVE	07/04/11	206.41KB	Share
MSB	Appendix 4D and Half Year Financial Report to 31 Dec 2010	PRICE SENSITIVE	28/02/11	625.04KB	Share
MSB	Appendix 4C - Strong Cash Position	PRICE SENSITIVE	31/01/11	353.14KB	Share
MSB	Response to ASX Price Query	PRICE SENSITIVE	13/01/11	193.53KB	Share
MSB	Cardiac Events, Mortality and Hospitalization Reduced	PRICE SENSITIVE	10/01/11	160.49KB	Share
MSB	Mesoblast Completes Acquisition of Angioblast	PRICE SENSITIVE	23/12/10	139.66KB	Share
MSB	Mesoblast And Cephalon Enter Into Strategic Alliance	PRICE SENSITIVE	08/12/10	200.21KB	Share
MSB	Trading Halt	PRICE SENSITIVE	06/12/10	263.55KB	Share
MSB	Mesoblast Clear To Proceed With Angioblast Acquisition	PRICE SENSITIVE	19/11/10	99.23KB	Share
MSB	Novel Heart Attack Treatment Results Presented to US Forum	PRICE SENSITIVE	16/11/10	140.28KB	Share
MSB	US Govt Grants for Further Development of Stem Cell Products	PRICE SENSITIVE	08/11/10	123.67KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/10	222.14KB	Share
MSB	Positive Results From Phase 2 Lumbar Fusion Trial	PRICE SENSITIVE	21/10/10	123.53KB	Share
MSB	Angioblast Stockholders Approve Acquisition By Mesoblast	PRICE SENSITIVE	20/10/10	119.61KB	Share
MSB	Mesoblast Targets Broader Cancer Indications	PRICE SENSITIVE	14/10/10	139.03KB	Share

MSB Key Patent Allowed In Japan For Heart Diseases, Stroke
27/03/15	PRICE SENSITIVE	73.02KB	Share
MSB Fast Track Access To Potential Japan Investment Incentives
19/03/15	PRICE SENSITIVE	84.21KB	Share
MSB Results Show Improved Survival in Children with GVHD
16/02/15	PRICE SENSITIVE	345.52KB	Share
MSB Half Yearly Report and Accounts
12/02/15	PRICE SENSITIVE	499.71KB	Share
MSB Key US patent granted for treatment of degenerated discs
10/02/15	PRICE SENSITIVE	67.56KB	Share
MSB Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	259.08KB	Share
MSB P3 trial initiated, positive 24 mth P2 results in back pain
15/01/15	PRICE SENSITIVE	99.1KB	Share
MSB Key Mesoblast Patent Claims Upheld in Europe
16/12/14	PRICE SENSITIVE	84.5KB	Share
MSB Chronic Low Back Pain Results Presented at NASS
13/11/14	PRICE SENSITIVE	1.11MB	Share
MSB Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	253.61KB	Share
MSB MSB PARTNER JCR FILES FOR PRODUCT APPROVAL
01/10/14	PRICE SENSITIVE	286.25KB	Share
MSB MSB Unveils Path to Bring its Key Products to Market
26/08/14	PRICE SENSITIVE	423.24KB	Share
MSB Preliminary Final Report
26/08/14	PRICE SENSITIVE	1.53MB	Share
MSB MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure
07/08/14	PRICE SENSITIVE	90.85KB	Share
MSB Appendix 4C - quarterly
31/07/14	PRICE SENSITIVE	255.04KB	Share
MSB Circulation Publishes Improved Outcomes with Mesoblast Cells
25/06/14	PRICE SENSITIVE	339.78KB	Share
MSB Mesoblast Receives $5.05m for Stem Cell Pipeline Development
16/06/14	PRICE SENSITIVE	61.45KB	Share
MSBResponse to ASX Price Query
06/06/14	PRICE SENSITIVE	115.33KB	Share
MSBMSB Accelerates Plans for Commercial Manufacturing Operation
28/05/14	PRICE SENSITIVE	248.58KB	Share
MSBAppendix 4C - quarterly
30/04/14	PRICE SENSITIVE	187.82KB	Share
MSBMESOBLAST PROVIDES UPDATE ON CLINICAL PROGRAMS OF PROCHYMAL
29/04/14	PRICE SENSITIVE	153.9KB	Share
MSBResponse to ASX price query
08/04/14	PRICE SENSITIVE	227.71KB	Share
MSBHalf Yearly Report and Accounts
26/02/14	PRICE SENSITIVE	360KB	Share
MSBKey European Patent Granted for Mesoblast's MPCs
20/02/14	PRICE SENSITIVE	102.94KB	Share
MSBAppendix 4C - quarterly
31/01/14	PRICE SENSITIVE	245.07KB	Share
MSBPositive Disc Repair Results Using Mesoblast Stem Cells
30/01/14	PRICE SENSITIVE	345.69KB	Share
MSBMesoblast Reports Positive Type 2 Diabetes Trial Results
04/12/13	PRICE SENSITIVE	335.25KB	Share
MSBNew Japanese Regenerative Medicine Legislation
25/11/13	PRICE SENSITIVE	282.6KB	Share
MSBMPCs Strengthen Cardiac Function in End-Stage Heart Failure
19/11/13	PRICE SENSITIVE	253.28KB	Share
MSBImproved Survival in Children with GvHD After Cell Therapy
14/11/13	PRICE SENSITIVE	110.33KB	Share
MSBMPCs Induce Functional Recovery in Ischemic Stroke Model
11/11/13	PRICE SENSITIVE	99.23KB	Share
MSBFDA Clears Phase 3 Heart Failure Trial
31/10/13	PRICE SENSITIVE	119.64KB	Share
MSBMSBs Registration Plans for GVHD Cell Product in Japan
28/10/13	PRICE SENSITIVE	84.06KB	Share
MSBAppendix 4C - quarterly
25/10/13	PRICE SENSITIVE	160.91KB	Share
MSBMesoblast, Intrexon and Ziopharm to Target Cancers
24/10/13	PRICE SENSITIVE	516.36KB	Share
MSBMesoblast Acquires Osiris' Cultured Stem Cell Business
11/10/13	PRICE SENSITIVE	124.44KB	Share
MSBPreliminary Final Report
29/08/13	PRICE SENSITIVE	741.39KB	Share
MSBAppendix 4C - quarterly
01/08/13	PRICE SENSITIVE	185.86KB	Share
MSBMSB Receives $4.3M Pipeline Funds from Australian Government
18/07/13	PRICE SENSITIVE	61.17KB	Share
MSBMSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
26/06/13	PRICE SENSITIVE	130.63KB	Share
MSBKey Mesenchymal Precursor Cell Patent Granted in Japan
05/06/13	PRICE SENSITIVE	102.76KB	Share
MSBCirculation Research Publishes AMI Preclinical Trial Results
15/05/13	PRICE SENSITIVE	225.19KB	Share
MSBAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	169.64KB	Share
MSBPOSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIR
22/04/13	PRICE SENSITIVE	386.62KB	Share
MSBMesoblast Enters into Agreements to Raise A$170million
06/03/13	PRICE SENSITIVE	366.18KB	Share
MSBTrading Halt
04/03/13	PRICE SENSITIVE	197.58KB	Share
MSBHalf-Year Results & Strategic Update on Product Development
11/02/13	PRICE SENSITIVE	339.47KB	Share
MSBHalf Yearly Report and Accounts
11/02/13	PRICE SENSITIVE	369.39KB	Share
MSBKEY MPC PATENTS GRANTED IN UNITED STATES AND CHINA
07/02/13	PRICE SENSITIVE	53.33KB	Share
MSBAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	184.56KB	Share
MSBFDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS
30/01/13	PRICE SENSITIVE	63.82KB	Share
MSBPositive Results in Phase 2 Lumbar Spinal Fusion Trial
11/01/13	PRICE SENSITIVE	230.78KB	Share
MSBMesoblast Corporate Overview - CEO Message to AGM
29/11/12	PRICE SENSITIVE	233.18KB	Share
MSBKey Manufacturing Agreement with FDA for Phase 3 Trials
20/11/12	PRICE SENSITIVE	130.26KB	Share
MSBPrice Query
15/11/12	PRICE SENSITIVE	166.61KB	Share
MSBAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	185.41KB	Share
MSBPreliminary Final Report
22/08/12	PRICE SENSITIVE	1.69MB	Share
MSBAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	174.29KB	Share
MSBRheumatoid Arthritis New Major Clinical Target for MSB
24/07/12	PRICE SENSITIVE	159.97KB	Share
MSBResponse to ASXPrice Query
18/06/12	PRICE SENSITIVE	190.73KB	Share
MSBMSB Provides Corporate Strategy For Neurologic Product
08/06/12	PRICE SENSITIVE	1MB	Share
MSBAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	189.32KB	Share
MSBIntervertebral Disc Repair Phase 2 Trial Update
17/04/12	PRICE SENSITIVE	129.89KB	Share
MSBHalf Yearly Report and Accounts
27/02/12	PRICE SENSITIVE	553.2KB	Share
MSBFDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
31/01/12	PRICE SENSITIVE	151.27KB	Share
MSBAppendix 4C - quarterly
12/01/12	PRICE SENSITIVE	130.08KB	Share
MSBPositive Outcome From FDA Meeting For Diabetes Program
22/11/11	PRICE SENSITIVE	213.39KB	Share
MSBPositive Heart Failure Trial Results Presented to AHA
15/11/11	PRICE SENSITIVE	226.43KB	Share
MSBPositive Results Using Adult Stem Cells for Type 2 Diabetes
10/11/11	PRICE SENSITIVE	795.25KB	Share
MSBAppendix 4C - quarterly
31/10/11	PRICE SENSITIVE	132.31KB	Share
MSBResponse to ASX Price Query Letter
28/10/11	PRICE SENSITIVE	179.75KB	Share
MSBClearance for First Phase 2 Clinical Trial for Eye Diseases
24/10/11	PRICE SENSITIVE	228.55KB	Share
MSBLicensing Executives Society Deals of Distinction Award
20/10/11	PRICE SENSITIVE	198.97KB	Share
MSBMSB and Lonza form strategic global manufacturing alliance
27/09/11	PRICE SENSITIVE	29.85KB	Share
MSBFirst European Trial for Heart Attack Treatment Cleared
05/09/11	PRICE SENSITIVE	227.7KB	Share
MSBPreliminary Final Report
24/08/11	PRICE SENSITIVE	599.08KB	Share
MSBFirst Minimally Invasive Procedure for Lumbar Disc Repair
22/08/11	PRICE SENSITIVE	202.43KB	Share
MSBAppendix 4C - quarterly
01/08/11	PRICE SENSITIVE	177.38KB	Share
MSBFDA Clearance for Phase 3 Bone Marrow Transplant Trial
07/07/11	PRICE SENSITIVE	230.27KB	Share
MSBFDA Clears Phase 2 Trial to Treat Degenerative Disc Disease
29/06/11	PRICE SENSITIVE	144.65KB	Share
MSBKey Product Franchises Featured at Nomura Asia Equity Forum
14/06/11	PRICE SENSITIVE	960.14KB	Share
MSBRevascor Increases Blood Supply to Damaged Heart Muscle
09/06/11	PRICE SENSITIVE	252.13KB	Share
MSBKey USA Patents Increase Commercial Rights and Indications
24/05/11	PRICE SENSITIVE	145.42KB	Share
MSBAppendix 4C - quarterly
02/05/11	PRICE SENSITIVE	128.9KB	Share
MSBMesoblast Included in S and P/ASX 200 Index
18/04/11	PRICE SENSITIVE	153.75KB	Share
MSBMesoblast Update on Valeant Proposal to Cephalon
07/04/11	PRICE SENSITIVE	206.41KB	Share
MSBAppendix 4D and Half Year Financial Report to 31 Dec 2010
28/02/11	PRICE SENSITIVE	625.04KB	Share
MSBAppendix 4C - Strong Cash Position
31/01/11	PRICE SENSITIVE	353.14KB	Share
MSBResponse to ASX Price Query
13/01/11	PRICE SENSITIVE	193.53KB	Share
MSBCardiac Events, Mortality and Hospitalization Reduced
10/01/11	PRICE SENSITIVE	160.49KB	Share
MSBMesoblast Completes Acquisition of Angioblast
23/12/10	PRICE SENSITIVE	139.66KB	Share
MSBMesoblast And Cephalon Enter Into Strategic Alliance
08/12/10	PRICE SENSITIVE	200.21KB	Share
MSBTrading Halt
06/12/10	PRICE SENSITIVE	263.55KB	Share
MSBMesoblast Clear To Proceed With Angioblast Acquisition
19/11/10	PRICE SENSITIVE	99.23KB	Share
MSBNovel Heart Attack Treatment Results Presented to US Forum
16/11/10	PRICE SENSITIVE	140.28KB	Share
MSBUS Govt Grants for Further Development of Stem Cell Products
08/11/10	PRICE SENSITIVE	123.67KB	Share
MSBAppendix 4C - quarterly
29/10/10	PRICE SENSITIVE	222.14KB	Share
MSBPositive Results From Phase 2 Lumbar Fusion Trial
21/10/10	PRICE SENSITIVE	123.53KB	Share
MSBAngioblast Stockholders Approve Acquisition By Mesoblast
20/10/10	PRICE SENSITIVE	119.61KB	Share
MSBMesoblast Targets Broader Cancer Indications
14/10/10	PRICE SENSITIVE	139.03KB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.31		Change 0.015(0.66%)		Mkt cap ! $2.950B

Open	High	Low	Value	Volume
$2.31	$2.33	$2.30	$1.453M	627.7K

Buyers (Bids)

No.	Vol.	Price($)
41	36955	$2.30

Sellers (Offers)

Price($)	Vol.	No.
$2.31	132272	24

View Market Depth

No.	Vol.	Price($)
25	34055	2.300
18	121071	2.290
15	97370	2.280
11	63955	2.270
10	91797	2.260

Price($)	Vol.	No.
2.310	13881	9
2.320	90275	24
2.330	95602	24
2.340	78927	13
2.350	160749	18

Last trade - 10.54am 13/08/2025 (20 minute delay)


Last $2.31		Change 0.015 ( 0.97 %)
Open	High	Low	Volume
$2.32	$2.33	$2.30	213292
Last updated 11.12am 13/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories